Physician profile
Benjamin Jones
NPI 1629482419
$1,013.86
in general payments reported to CMS, 2019-2025
15 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2021: $33.33 · 2022: $95.16 · 2023: $66.44 · 2024: $224 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $330.53 | 2019-2024 | |
| Novo Nordisk INC | $154.50 | 2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $116.62 | 2024 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $85.43 | 2024-2025 | Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $58.90 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $46.47 | 2025 | |
| Abbott Laboratories | $42.92 | 2025 | |
| Genzyme Corporation | $31.89 | 2025 | |
| Amgen INC. | $28.78 | 2025 | Otezla, Repatha |
| Corcept Therapeutics | $22.14 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.06 | 2025 | Xifaxan |
| Axsome Therapeutics, INC. | $21.48 | 2025 | Symbravo |
| Alnylam Pharmaceuticals INC. | $19.32 | 2025 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.20 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $14.62 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.